Home/Pipeline/INT301 (implied)

INT301 (implied)

Peanut Allergy

Pre-clinicalActive

Key Facts

Indication

Peanut Allergy

Phase

Pre-clinical

Status

Active

Company

Intrommune Therapeutics

About Intrommune Therapeutics

Intrommune Therapeutics is a clinical-stage biotech developing a disruptive drug delivery platform for food allergy immunotherapy. Its lead program, INT301, encapsulates allergenic proteins in a toothpaste, enabling daily treatment through routine brushing to desensitize patients via the oral mucosa. The company is targeting a large and growing unmet medical need with a treatment designed to improve adherence and quality of life over current burdensome options. Led by a management team with legal, financial, and clinical expertise, Intrommune is advancing its OMIT platform through clinical development.

View full company profile

Therapeutic Areas

Allergy & Immunology Food Allergy

Other Peanut Allergy Drugs

Drug	Company	Phase	Status
PRT120	Prota Therapeutics	Phase 3	Active
INP20	InnoUp	Clinical	Active
Food Allergy Program	Hal Allergy	Clinical Development	Active
Peanut allergy program	Desentum	Unknown	Active
Peanut Oral Immunotherapy	Camallergy	Phase 2	Active
Ukko-Peanut	Ukko	Preclinical	Active
VLP Peanut (VLP-p)	Allergy Therapeutics	Phase II	Active